Clinical trial NCT03255824
Conditions: Anesthesia
Keywords: Oral Surgery Third Molars Intravenous Sedation Dexmedetomidine
Sponsor: Montefiore Medical Center
Start date: 2018-03-20; Completion date: 2019-12-27
Enrollment: 144 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
Hypothesis: A combination of midazolam with dexmedetomidine for sedation during third molar surgery will provide 1) superior patient satisfaction, 2) superior operator satisfaction and 3) no significant hemodynamic or respiratory changes when compared to a sedation combination of midazolam, fentanyl and propofol for sedation during third molar surgery.

Detailed description:
Intravenous sedation (IVS) is an integral aspect of the oral and maxillofacial surgeon's practice. For many minor oral surgical procedures, intravenous sedation is often necessary to manage patient anxiety and discomfort, while also facilitating a safe and efficient procedure in the outpatient setting. Ideally, sedative agents have anxiolytic, amnestic, and analgesic properties while maintaining cardiopulmonary stability. The medications used should allow for rapid onset of action, as well as a quick recovery, with minimal side effects.

Several pharmacologic agents are frequently used for conscious sedation in the oral surgery practice. These medications often include midazolam, fentanyl, ketamine and propofol, either alone or in conjunction with one another. While propofol and fentanyl have proved to be efficacious agents for use in intravenous sedation, they are not without associated side effects. Propofol has the potential to cause a quick progression from conscious sedation to general anesthesia, with the undesired effect of associated cardiovascular and respiratory depression. Decreased respiratory drive, hypotension, and dose-dependent bradycardia are often seen with opioid analgesics such as fentanyl.1,2 Ketamine can cause emergence delirium, increased salivation and pulmonary secretions, tachycardia, and post-operative nausea and vomiting (PONV).

Midazolam is a benzodiazepine that is an attractive agent for intravenous sedation due to its sedative, amnestic, and hypnotic properties. In addition, it is associated with very minimal cardiovascular and respiratory changes. However, midazolam lacks significant analgesic effects, and therefore is routinely used in conjunction with additional agents when used for procedural sedation. Though several studies have explored the use of midazolam as a sole anesthetic, very high doses are required for deep sedation. This can lead to dose-dependent respiratory depression, prolonged emergence and longer recovery time.

Dexmedetomidine (Precedex, Hospira, Inc., Lake Forest, IL) is a highly selective alpha2-adrenergic agonist that possesses hypnotic, sedative, anxiolytic, and analgesic properties. It is currently approved for use as a sedative agent in ICU patients, and has been proven a safe and effective agent for use during procedural sedation. In the central nervous system, the primary site of action of dexmedetomidine is the locus ceruleus, resulting in a level of sedation similar to natural sleep, associated with fast and easy arousal. It demonstrates relative hemodynamic stability with little effect on respiratory depression. Unlike propofol and fentanyl, dexmedetomidine's lack of adverse effects on respiration makes it an attractive agent for use during intravenous sedation in the oral and maxillofacial surgery practice.

Several studies involving dexmedetomidine exist in the oral and maxillofacial surgery literature. Dexmedetomidine has been compared as a substitute for midazolam, as well as propofol, in conscious sedation by several authors. For third molar surgery, dexmedetomidine was noted to preserve the respiratory rate and oxygen saturation throughout operation and recovery periods. Fan et al also found no significant differences in respiratory rate when comparing the two agents for conscious sedation. In comparison to midazolam, Ryu et al reported safe sedation without airway compromise and minimal effects on the respiratory system.

Dexmedetomidine also possesses sympatholytic properties, and is commonly associated with a dose-dependent decrease in both heart rate and blood pressure.4,9 Taniyama et al compared dexmedetomidine to propofol for intravenous sedation for minor oral surgical procedures. They found that dexmedetomidine lead to significant hemodynamic changes during the initial loading infusion. An initial increase in blood pressure was seen, followed by a significant decrease in both systolic and diastolic blood pressure, as well as heart rate. These variations are attributed to the fact that dexmedetomidine does not have selectivity for alpha-2A versus alpha-2B receptors. While alpha-2A receptors are found in the CNS and are therefore responsible for the analgesic and sedative effects of the drug, alpha-2B receptors are found in vascular smooth muscle and thereby mediate the hypertensive effects of high doses of dexmedetomidine. Because of this, initial loading doses of dexmedetomidine may be associated with a transient increase in blood pressure, followed by an overall reduction in blood pressure and heart rate from baseline. Hall et al reported that dexmedetomidine demonstrated a decrease in heart rate from baseline between 16 and 18%, and a decrease in blood pressure of 10 to 20%.15 However, in some studies, similar biphasic changes were not observed, possibly due to the use of a lower dosage of dexmedetomidine.

Aside from dose-dependent depression of the cardiovascular system, dexmedetomidine has been associated with minimal to no amnesic effects. One other possible disadvantage of dexmedetomidine as a sedative agent for in-office procedures is the increased postoperative recovery time. Peak sedative effects of the drug occur approximately 90-105 minutes after administration, continuing to as much as 180 minutes. This may necessitate post-operative observation periods of increased duration. Intravenously administered dexmedetomidine has a distribution half-life of 6 minutes and an elimination half-life of 2 hours. It undergoes biotransformation in the liver and is excreted primarily in the urine.

The purpose of this study is to measure the relative efficacy (sedation, analgesia, operating conditions, and patient satisfaction) and safety (hemodynamic and respiratory changes) of dexmedetomidine and midazolam compared to the traditional combination of midazolam, fentanyl, and propofol in office based intravenous sedation for extraction of third molars.

Arms: arm 1: Group of patients to be administered a standard Propofol, Midazolam, Fentanyl anesthesia combination. arm 2: Group of patients to be administered the Dexmedetomidine and Midazolam anesthesia combination.
Interventions: intervention 1: Dexmedetomidine and Midazolam intervention 2: Propofol, Midazolam, and Fentanyl
Intervention descriptions: intervention 1: Administration of Dexmedetomidine and Midazolam for sedation during third molar surgery. intervention 2: Administration of Propofol, Midazolam, and Fentanyl for sedation during third molar surgery.

Protocol documents:
Prot_SAP_000.pdf: 
A Comparison of Dexmedetomidine Versus Propofol for Use in Intravenous Sedation    
NCT03255824 
ID: 2016-6953    
Document date: 7/12/2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


BACKGROUND/SIGNIFICANCE 
Intravenous sedation (IVS) is an integral aspect of the oral and maxillofacial surgeon’s practice. For many 
minor oral surgical procedures, intravenous sedation is often necessary to manage patient anxiety and 
discomfort, while also facilitating a safe and efficient procedure in the outpatient setting.  Ideally, 
sedative agents have anxiolytic, amnestic, and analgesic properties while maintaining cardiopulmonary 
stability.  The medications used should allow for rapid onset of action, as well as a quick recovery, with 
minimal side effects. 
Several pharmacologic agents are frequently used for conscious sedation in the oral surgery practice.  
These medications often include midazolam, fentanyl, ketamine and propofol, either alone or in 
conjunction with one another.  While propofol and fentanyl have proved to be efficacious agents for use 
in intravenous sedation, they are not without associated side effects.  Propofol has the potential to 
cause a quick progression from conscious sedation to general anesthesia, with the undesired effect of 
associated cardiovascular and respiratory depression.1,2  Decreased respiratory drive, hypotension, and 
dose-dependent bradycardia are often seen with opioid analgesics such as fentanyl.1,2  Ketamine can 
cause emergence delirium, increased salivation and pulmonary secretions, tachycardia, and post-
operative nausea and vomiting (PONV).3 
Midazolam is a benzodiazepine that is an attractive agent for intravenous sedation due to its sedative, 
amnestic, and hypnotic properties.  In addition, it is associated with very minimal cardiovascular and 
respiratory changes.4,5  However, midazolam lacks significant analgesic effects, and therefore is routinely 
used in conjunction with additional agents when used for procedural sedation.  Though several studies 
have explored the use of midazolam as a sole anesthetic, very high doses are required for deep 
sedation.  This can lead to dose-dependent respiratory depression, prolonged emergence and longer 
recovery time.4,6 
Dexmedetomidine (Precedex, Hospira, Inc., Lake Forest, IL) is a highly selective alpha2-adrenergic 
agonist that possesses hypnotic, sedative, anxiolytic, and analgesic properties.1,5,7-9  It is currently 
approved for use as a sedative agent in ICU patients, and has been proven a safe and effective agent for 
use during procedural sedation.1,6,9,10  In the central nervous system, the primary site of action of 
dexmedetomidine is the locus ceruleus, resulting in a level of sedation similar to natural sleep, 
associated with fast and easy arousal.7,11,12  It demonstrates relative hemodynamic stability with little 
effect on respiratory depression.1,5  Unlike propofol and fentanyl, dexmedetomidine’s lack of adverse 
effects on respiration makes it an attractive agent for use during intravenous sedation in the oral and 
maxillofacial surgery practice.   
Several studies involving dexmedetomidine exist in the oral and maxillofacial surgery literature.  
Dexmedetomidine has been compared as a substitute for midazolam, as well as propofol, in conscious 
sedation by several authors.  For third molar surgery, dexmedetomidine was noted to preserve the 
respiratory rate and oxygen saturation throughout operation and recovery periods.4  Fan et al also found 
no significant differences in respiratory rate when comparing the two agents for conscious sedation.5  In 
comparison to midazolam, Ryu et al reported safe sedation without airway compromise and minimal 
effects on the respiratory system.13 
Dexmedetomidine also possesses sympatholytic properties, and is commonly associated with a dose-
dependent decrease in both heart rate and blood pressure.4,9 Taniyama et al compared dexmedetomidine 


to propofol for intravenous sedation for minor oral surgical procedures.  They found that 
dexmedetomidine lead to significant hemodynamic changes during the initial loading infusion.14  An initial 
increase in blood pressure was seen, followed by a significant decrease in both systolic and diastolic blood 
pressure, as well as heart rate.  These variations are attributed to the fact that dexmedetomidine does 
not have selectivity for alpha-2A versus alpha-2B receptors.14  While alpha-2A receptors are found in the 
CNS and are therefore responsible for the analgesic and sedative effects of the drug, alpha-2B receptors 
are found in vascular smooth muscle and thereby mediate the hypertensive effects of high doses of 
dexmedetomidine.  Because of this, initial loading doses of dexmedetomidine may be associated with a 
transient increase in blood pressure, followed by an overall reduction in blood pressure and heart rate 
from baseline.4,12,15 Hall et al reported that dexmedetomidine demonstrated a decrease in heart rate from 
baseline between 16 and 18%, and a decrease in blood pressure of 10 to 20%.15  However, in some studies, 
similar biphasic changes were not observed, possibly due to the use of a lower dosage of 
dexmedetomidine.4 
Aside from dose-dependent depression of the cardiovascular system, dexmedetomidine has been 
associated with minimal to no amnesic effects.4  One other possible disadvantage of dexmedetomidine 
as a sedative agent for in-office procedures is the increased postoperative recovery time.6  Peak sedative 
effects of the drug occur approximately 90-105 minutes after administration, continuing to as much as 
180 minutes.13  This may necessitate post-operative observation periods of increased duration.  
Intravenously administered dexmedetomidine has a distribution half-life of 6 minutes and an 
elimination half-life of 2 hours.12  It undergoes biotransformation in the liver and is excreted primarily in 
the urine.9  
 
PURPOSE 
The primary goal of this prospective randomized trial is to determine whether there is a significant 
difference in the number of respiratory events requiring intervention during the intravenous deep 
sedation/general anesthesia (DS/GA) between two different anesthetic medication combinations: 
midazolam and dexmedetomidine versus midazolam, fentanyl, and propofol. 
Secondary variables to be measured include hemodynamic changes during the sedation, difference in 
the amount of movement during injection of local anesthesia, time until discharge, patient satisfaction 
with the sedation, and surgeon satisfaction with the sedation. 
 
HYPOTHESIS 
A sedative combination of midazolam with dexmedetomidine for intravenous DS/GA during third molar 
surgery will provide less respiratory events requiring intervention when compared to a sedative 
combination of midazolam, fentanyl, and propofol. 
 
STUDY DESIGN 


The proposed study is a prospective, randomized, controlled trial, with two intravenous treatment 
groups during third molar surgery.  The patient will be masked to the anesthetic protocol used during 
the IVS for third molar surgery, and there will be a masked independent scorer to evaluate the number 
of respiratory events requiring intervention during sedation, extent of patient movements, facial 
expressions and vocalization during local anesthesia injection, and time of procedure, time to 
ambulation, and time of virtual discharge.   
Group 1 (Control): Midazolam/fentanyl/propofol (MFP)  
Group 2 (Study): Dexmedetomidine/midazolam (D/M) 
Primary Outcomes 
1. To compare the groups regarding the number of respiratory events requiring intervention, 
described as: 
a. Chin lift/jaw thrust 
b. Tongue trust 
c. Yankauer suctioning 
d. Positive pressure O2 
e. Placement of an oral or nasal airway 
 
Secondary Outcomes 
 
1. To compare the groups regarding movement of the patient during the first injection of local 
anesthesia during the IVS at time of injection measured using the Scorer Assessment Form 
(Appendix A), which includes: 
a.  The Behavioral Pain Scale – Non-Intubated patients (BPS-NI) (Figure 1) 
b. Cooperation Scale (Figure 2) at 5 and 15 minutes 
 
 
 
 
Figure 1. BPS-NI Scale 


                        
 
 
2. To compare patient satisfaction of treatment using D/M versus MFP combinations   
a. Patient Satisfaction Survey: VAS; measuring overall satisfaction with the IVS and 
memory of procedure (Appendix B) 
 
3. To compare the surgeon satisfaction of the IVS using D/M versus MFP combinations 
a. Surgeon Satisfaction Survey (Appendix C) 
b. Cooperation Scale (Figure 2) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Cooperation Scale 


  
 
 
4. To compare the differences in hemodynamic stability using a D/M combination compared to the 
MFP combination.  (In this study, a deviation from baseline of both the blood pressure and heart 
rate by 20% or greater will be considered clinically significant) 
a. Change in heart rate (change ≥ 20 BPM) 
b. Change in blood pressure (NIBP) (change ≥ 20%) 
 
5. To assess whether a D/M combination leads to a significant change in respiratory depression 
compared to the MFP combination.   
a. Change in respiratory rate (change ≥ 20%) 
b. Change in arterial oxygen saturation (as measured by pulse oximeter)  
i. number of events of ≤92% 
 
6. To assess whether a D/M combination increases postoperative recovery time when compared 
the MFP combination.   
a. Duration of procedure 
b. Time to ambulation (to recovery room) 
c. Time to “virtual discharge” (comparative statistic) 
i. Aldrete score of ≥ 9 or pre-procedure score is met (Figure 3) 
ii. All subjects are required to stay a minimum of 30 minutes after the end of the 
procedure.  Therefore, at least two postoperative vital sign readings will be 
obtained. If the subject meets discharge criteria prior to 30 minutes, this time 
will be the “virtual discharge” time. 
 


Figure 3. Aldrete Score 
                                    
 
  
Randomization  
Subjects will be assigned to D/M or MFP by a computer-generated randomization scheme with an 
undisclosed blocking factor in accordance with a 1:1 randomization ratio.  A packet of sealed envelopes 
containing the randomization code and study ID will be provided to the anesthetist investigator who will 
be instructed to open the next envelope in sequence to determine the sedation the patient is to receive.  
He or she will record the patient's name on the sheet of paper and file it in the patient's chart. The 
patient's data will be de-identified by affixing the patient's study ID on all subsequent data files and 
forms associated with the patient for this trial. 
Investigator Team Roles 
Surgeon: Responsible for performing the surgery (masking is near impossible given that 
dexmedetomidine is colorless whereas propofol is white).  Furthermore, in the outpatient OMFS surgery 
clinic the patient’s airway is not secured with an endotracheal tube.  Masking the surgeon may be 
unsafe in this setting and thus will not be attempted. 
 
Anesthetist: Responsible for medication preparation and administration, recording of drug 
administration and vital signs, patient monitoring, monitoring of apneic events. The anesthetist will be 
unmasked by necessity and will not evaluate outcomes. 
 
Scorer: Responsible for recording and scoring the respiratory events requiring intervention, BPS-NI 
Scale, length of procedure, time to discharge, any adverse events or outcomes, and vital signs; scorer 
will be masked as to treatment group. 
 
Blinding   


Only the scorer will be masked. To preserve masking of the scorer, all medications, infusion pump, and 
IV tubing will be located behind a barrier to ensure that the scorer will not know the group to which the 
patient has been assigned.  In addition, the patient will not be informed as to their sedation, thus 
minimizing bias in determining patient satisfaction with treatment. 
METHODS 
1. Procedures to evaluate inclusion/exclusion 
a. Past medical history, medications, allergies 
b. Clinical examination 
c. Every patient will have a panoramic radiograph and a cone beam CT if required based on 
surgeon’s examination 
2. Informed consent followed by opening envelope to derive randomization group 
3. Procedures performed as part of the trial. 
a. NPO status performed by the anesthetist  
b. Standard ASA monitors including pulse oximetry, NIBP, three-lead EKG, capnography 
c. Pre-treatment vitals and BMI recorded by the anesthetist 
d. IV access obtained by the anesthetist or surgeon 
e. Administration of antibiotic and dexamethasone 
i. The subject will preoperatively be administered 600mg of clindamycin 
intravenously, unless the patient has a reported allergy, in which case an 
alternative antibiotic will be given.  In addition to the antibiotic, 8mg of 
dexamethasone will be given intravenously to aid in reducing postoperative 
edema. 
f. Supplemental oxygen will be provided via nasal cannula at 2 L/min 
g. Vital signs will be recorded every 5 minutes by scorer 
h. The scorer will document respiratory events requiring intervention (i.e. chin lift, positive 
pressure).  Required cessation of infusion or additional requested boluses will also be 
recorded. 
i. 
Anesthetist begins IVS  
i. Group 1 (control):  


1. 0.03mg/kg midazolam, 0.1 mcg/kg of fentanyl and an infusion of propofol 
at 125 mcg/kg/min 
2. Propofol boluses at 0.1 mg/kg 
ii. Group 2 (study): 
1. 0.03mg/kg midazolam, initial bolus of dexmedetomidine at 1 mcg/kg for 
10 minutes followed by a maintenance infusion of 0.5 mcg/kg/hr 
2. All medications, along with the infusion pump and IV tubing, will be 
located behind a barrier so that the scorer will not know which 
medications are  
j. 
Local anesthetic administration (2% lidocaine with 1:100,000 epinephrine) 
k. Operative procedure 
l. 
Anesthetic will be discontinued at initiation of suturing/closure 
m. The procedure completion time will be recorded by the scorer as the time at which the 
surgeon puts down the last instrument.   
n. Vitals will be obtained at the conclusion of the procedure and every 15 minutes thereafter 
until discharge.  Two sets of post op vital signs will be evaluated statistically for each 
patient (15 and 30 minutes). 
o. The patient will be discharged based on the criteria found on the modified Aldrete score 
(greater or equal to 9 or the preoperative score is met).  
4. Evaluations 
a. The surgeon will complete a Surgeon Satisfaction Survey regarding satisfaction with the 
IVS and the Cooperation Scale.   
b. The patient will complete the Patient Satisfaction Survey 
Stopping Criteria 
IVS will be stopped intraoperatively in this study as it would in the regular clinic setting.  If the procedure 
cannot be completed safely due to inability to control the patient from moving with the sedative agents, 
the procedure and sedation will be discontinued.  Other criteria to stop the IVS will include tachycardia 
>150bpm, bradycardia <40bpm, and/or inability to control the patient’s airway. 
IV medications will be temporarily stopped if a patient remains apneic or in laryngospasm after 
intervention.  The IV medication can be resumed later in the procedure. 
Patient Sample 


Inclusion Criteria   
 
• 
Age 18-35 with the ability to sign informed consent 
• 
Subject must have 3-4 partial or full bony impacted third molars requiring surgical extraction 
• 
ASA Class I or II 
• 
English-speaking and Spanish-speaking subjects 
 
 
Exclusion Criteria 
 
• 
ASA Class III or higher 
• 
Patients taking alpha-2 agonists or benzodiazepines 
• 
Allergy or drug reaction to any of the drugs used in this study (benzodiazepines, opioids, 
propofol, alpha-2 agonists, NSAIDs, local anesthetic) 
• 
BMI greater than 30 
• 
History of or current substance abuse or alcoholism 
• 
History of mood-altering medications, tranquilizers, or antidepressants. 
• 
Pregnant females  
 
 
Information Obtained  
 
As with any medical evaluation, the subject’s DOB, medical record number (MRN), full medical history, 
and history of present illness will be obtained.  
 
No human specimen or samples will be obtained.   
Risks 
 
Subjects in the study group are not at increased risk compared to the control group.  
 
Normal risks associated with third molar surgery will be discussed at your initial visit.  These include, but 
are not limited to, pain, bleeding, infection, swelling, damage to adjacent teeth/structures, temporary or 
permanent numbness of the lower lip/chin/cheek/gums/teeth and/or tongue, chronic sinusitis, 
oroantral communication, alveolar osteitis (dry socket), and the need for additional procedures.   
 
Risks associated with deep sedation/general anesthesia include, but are not limited to, headache, 
nausea, vomiting, allergic reaction, cardiac depression or arrest, respiratory depression or arrest, loss of 
protective reflexes including the ability to maintain an airway independently or respond to verbal 
commands or physical stimulation, aspiration, laryngospasm, bronchospasm, syncope, seizure, 
neurological impairment, or prolonged recovery from anesthesia. 
 
 
Benefits 
 


Subjects in the study group have no increased benefit over the control group. 
 
The benefit of removing third molars are to remove source of infection and pain, decreased chance of 
future infection, and decreased chance of future pathology. 
 
Data Safety Monitoring Plan 
Data will only be saved on one computer (password protected) at the Blondell Dental Clinic at 
Montefiore Medical Park in the primary investigator’s office (Dr. Patrick Nolan).  The subjects are 
assumed to present randomly and are assigned study numbers in sequence according to the exterior 
envelope label.  These study IDs are not associated with any personal identifiers with the following 
exceptions: 1) The patient's name and MRN will be recorded on the envelope (the envelope will be 
shredded at the end of the procedure), and 2) The study ID-medical record key will be saved in a 
separate database with a different password.  The questionnaire documents will be locked in a filing 
cabinet in the primary investigator’s office until the conclusion of the study when they will be shredded.  
In addition, safety findings will be provided to an independent statistician after 25%, 50%, and 75% of 
the patients have been followed for 6 weeks or longer. 
 
Consent forms and research records will be scanned into the subject’s electronic dental record. All other 
documentation will be shredded at the conclusion of the study. 
 
Data Safety Monitoring Committee 
 
1. Jason Baker, DMD  
Attending surgeon, Montefiore Medical Center  
Clinical Instructor, Albert Einstein College of Medicine 
 
2. Mauricio Wiltz, DDS 
Attending surgeon, Montefiore Medical Center  
Assistant Professor, Albert Einstein College of Medicine 
 
3. Kathy Freeman 
Statistician  
 
 
All adverse events will go to the IRB as well as the committee.  The committee will meet once a year to 
review all adverse events and to determine if any further protocol changes are necessary to ensure 
subject safety and to confirm that the risk vs. benefit has not changed. The committee will then submit a 
letter to the IRB after the meeting. 
 
Participant Recruitment and Informed Consent  
Patients requiring third molar extractions who meet the inclusion criteria for the study will be recruited.  
These patients are obtained via walk-in emergencies and referrals from within the Montefiore Medical 


Center general dental and orthodontic departments.  Patients will have the option of having the 
procedure done without IVS. 
Informed consent will be obtained by one of the investigators prior to IV placement. The full protocol 
including risks, benefits and alternatives will be provided to subjects in writing, and the subject will have 
the opportunity to ask questions. Consent will be available in English and Spanish with necessary 
interpreters. A third party will witness all consents.  Only subjects with capacity to sign informed consent 
will be included. Oral consent will also be obtained from the surgeons. 
 
The patient will receive a copy of the informed consent form. 
HIPAA authorization will also be provided and signed by every study participant. 
 
Statistical Analysis 
 
Observed respiratory adverse events in children given sedation were 6.1% on ketamine v. 19.3% on 
midazolam/fentanyl.18  The relative magnitude of these rates was consistent with the 5% v. 15% rates 
for respiratory adverse events presented in a power analysis for the comparison of IV and IM 
ketamine.19  Thus for α=.05, two-tailed test with 80% power, 114 subjects are required per group.  If 5% 
of subjects change their mind after randomization with regard to participating, then 120 are required 
per group. 
 
Descriptive statistics for continuous variables will be presented as means and standard deviations, or if 
non-normal, by medians and ranges.  Differences in means between groups at each time point will be 
presented as their difference with a 95% confidence interval for the difference, and displayed using a 
line plot with standard error bars.  Categorical variables will be summarized using relative frequency 
distributions, with differences between groups and associated 95% confidence intervals.  Histograms 
will be presented for non-normal continuous variables and relative frequencies. 
 
Comparison of the groups with regard to the proportion of patients with at least one adverse respiratory 
event requiring intervention during sedation will be assessed using a Fisher's Exact test. The distribution 
of the number rating score for patient satisfaction will be assessed (VAS scales have been supported for 
their ratio scale properties), and if assumptions are met, an optimal mixed effects model (with repeated 
measures over time) will be derived after evaluating various covariance matrix structures.  Because 
patient, physician, and grade of operating conditions will be evaluated at the end of the trial only, and 
because these scales are ordinal, Wilcoxon Rank Sum tests will be used.  To evaluate the differences in 
hemodynamic stability and respiratory rate, mixed effects models will be derived for heart rate, systolic 
and diastolic blood pressures, and respiratory rate considering repeated assessments over time.  For the 
number of O2 saturation events ≤92%, and for each of the numbers of respiratory events requiring 
intervention, Poisson regression with a log link function will be used; in addition multi (recurrent)-event 
survival models (i.e. Anderson-Gill; Wei-Lin-Weissfield; Prentice, Williams, Peterson) will be applied and 
the optimal model chosen to determine whether there is a significant difference in the relative number 
of events that occurred as well as the difference in the distribution (spacing) of these events over the 
observed time period.  To assess whether dexmedetomidine significantly increases postoperative 
recovery time when compared with propofol, a transformation of scale will be derived to better 


approximate normality, and a difference between the groups with regard to recovery times will be 
assessed using a t-test for independent samples.  This procedure will also be performed for time to 
ambulation and time to “virtual discharge.”  Because the Aldrete scale is ordinal and assessed only once, 
the difference between groups will be tested using a Wilcoxon Rank Sum test.  All tests of hypotheses 
will follow an intention-to-treat protocol, will be two-tailed with α=.05, and performed using SAS 
Version 9.3, Cary, NC. Results will follow CONSORT guidelines.  The trial will be registered with 
clinicaltrials.gov. 
 
Cost 
The subjects’ insurance will be billed for the treatment.  There will be no additional cost to the patient.  
There will be no reimbursement for travel or compensation for participation. 
 
Collaborations 
o Results of the study will be shared Montefiore IRB.  This information will contain no 
identifiers of the involved subjects 
 
REFERENCES 
1. Eberl S, et al.  Safety and efficacy using dexmedetomidine versus propofol TCI sedation during 
oesophagus interventions: a randomized trial.  BMC Gastroenterology 2013; 13: 176. 
2. Parworth L, Frost D, Zuniga J, Bennett T.  Propofol and Fentanyl Compared With Midazolam and 
Fentanyl During Third Molar Surgery.  J Oral Maxillofac Surg (1998) 56: 447-453. 
3. Jun NH, Shim JK, et al.  Effect of ketamine pretreatment for patients undergoing percutaneous 
transluminal balloon angioplasty with continuous remifentanyl infusion.  Korean J Anesthesiol. 
(2011) 61(4): 308-14.  https://doi.org/10.4097/kjae.2011.61.4.308 
4. Ustün Y, Gündüz M, et al. Dexmedetomidine versus midazolam in outpatient third molar surgery.  
J Oral Maxillofac Surg (2006) 64(9):1353-58. 
5. Fan TW, Ti LK, Islam I.  Comparison of dexmedetomidine and midazolam for conscious sedation in 
dental surgery monitored by bispectral index. Br J Oral Maxillofac Surg (2013) 51:428-33. 
6. Makary L, Vornik V, Finn R, et al.  Prolonged recovery associated with dexmedetomidine when 
used as a sole sedative agent in office-based oral and maxillofacial surgery procedures. J Oral 
Maxillofac Surg (2010) 68:386–91. 
7. Cheung CW, Yink CLA, Chiu WK, et al.  A comparison of dexmedetomidine and midazolam for 
sedation in third molar surgery.  Anaesthesia (2007) 62: 1132-8. 
8. Cheung CW, Ng KFJ, Liu J, et al.  Analgesic and sedative effects of intranasal dexmedetomidine in 
third molar surgery under local anaesthesia.  Br J Anaesthesia (2011) 107(3): 430-7. 


9. Bhana N, Goa KL, McClellan KJ.  Dexmedetomidine.  Drugs (2000) 59: 263-70. 
10. Jaakola ML. Dexmedetomidine premedication before intravenous regional anesthesia in minor 
outpatient hand surgery.  J Clin Anesth (1994) 6:204. 
11. Nooh N, Sheta SA, Abdullah WA, et al.  Intranasal atomized dexmedetomidine for sedation during 
third molar extraction.  Int J Oral Maxillofac Surg  (2013) 42: 857. 
12. Smiley MK, Prior SR.  Dexmedetomidine Sedation With and Without Midazolam for Third Molar 
Surgery. Anesth Prog (2014) 61: 3-10. 
13. Ryu D-S, Lee D-W, Choi SC, Oh I-H.  Sedation Protocol Using Dexmedetomidine for Third Molar 
Extraction.  J Oral Maxillofac Surg (2016) 74:926.e1-926.e7. 
14. Taniyama K, Oda H, Okawa K, et al.  Psychosedation with dexmedetomidine hydrochloride during 
minor oral surgery. Anesth Prog (2009) 56:75–80. 
15. Hall JE, Uhrich TD, Barney JA, et al.  Sedative, amnestic, and analgesic properties of small-dose 
dexmedetomidine infusions. Anesth Analg (2000) 90:699–705. 
16. Chanques G, Payen JF, Mercier G, et al.  Assessing pain in non-intubated critically ill patients 
unable to self report: an adaptation of the Behavioral Pain Scale. Intensive Care Med (2009) 35: 
2060-2067. 
17. Barone C, Pablo C, Barone G.  Postanesthetic Care in the Critical Care Unit. Crit Care Nurse (2004) 
24: 38-45.  
18. Roback MG, Walthen JE, Bajaj L, Bothner J.  Adverse events associated with procedural sedation 
and analgesia in a pediatric emergency department: a comparison of common parenteral drugs.  
Acad Emerg Med (2005) 12(6): 508-13. 
19. Roback MG, Walthen JE, MacKenzie T, Bajaj L.  A Randomized, Controlled Trial of IV Versus IM 
Ketamine for Sedation of Pediatric Patients Receiving Emergency Department Orthopedic 
Procedures.  Ann Emerg Med (2006) 48(5): 605-12.